Compare Quest Diagnostics Inc (DGX) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Petróleo Brasileiro SA — how do they compare? Quest Diagnostics Inc trades at $237.33 (market cap $26.21B), while Petróleo Brasileiro SA trades at $17.92 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 4.3× Quest Diagnostics Inc's market cap, and Petróleo Brasileiro SA pays the higher dividend (9.42%). Which is the better fit depends on your goals.
| DGX | PBR | |
|---|---|---|
Market Cap | $26.21B | $112.19B |
Sector | Health | Technology |
52-Week High | $238.50 | $22.03 |
52-Week Low | $173.49 | $11.54 |
Enterprise Value | $31.97B | $172.61B |
Dividend Yield | 1.45% | 9.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
PBR trades at $17.91, down 2.29% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a low P/E of 4.53 and robust profitability with a 24.52% net income margin. Recent Q2 2026 earnings beat expectations, with net profit nearly doubling year-over-year, driven by record production and higher oil prices (Reuters, 2026-08-06).
The investment case is supported by attractive valuations and strong cash flows, but faces headwinds from technical selling pressure and regulatory uncertainty. Analyst consensus is bullish with 50% buy ratings, though near-term price action may remain volatile amid broader market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
